Log In Sign up
The largest database of trusted experimental protocols

Female k18 hace2 transgenic mice

Manufactured by Jackson ImmunoResearch
Visit Supplier

The Female K18-hACE2 transgenic mice express the human angiotensin-converting enzyme 2 (hACE2) gene under the control of the cytokeratin-18 (K18) promoter. These mice are used in research applications, but a detailed unbiased description without extrapolation is not available.

Automatically generated - may contain errors

Lab products found in correlation

Female cd 1 igs mice, by Charles River Laboratories (2 mentions)

Spelling variants of this product

K18-hACE2 mice (39 citations) K18-hACE2 (21 citations) K18-hACE2 transgenic mice (15 citations)

4 protocols using female k18 hace2 transgenic mice

1

Evaluating SARS-CoV-2 Antibody Treatments in Transgenic Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Female K18-hACE2 transgenic mice were purchased from Jackson laboratory and maintained in pathogen-free conditions and handling conforms to the requirements of the National Institutes of Health and the Scripps Research Institute Animal Research Committee. 8–12 weeks old mice (weight range of 16.2–29.1 g) were infected intranasally with 10,000 PFU of SARS-COV-2 in total volume 50 μL different concentration of AB were injected intravenously 1 h post infection or by intranasal instillation 12 h post infection using Palivizumab as the Isotype control, STI-9167 or STI-9199 depending on the route of administration.
Duty J.A., Kraus T., Zhou H., Zhang Y., Shaabani N., Yildiz S., Du N., Singh A., Miorin L., Li D., Stegman K., Ophir S., Cao X., Atanasoff K., Lim R., Mena I., Bouvier N.M., Kowdle S., Carreño J.M., Rivero-Nava L., Raskin A., Moreno E., Johnson S., Rathnasinghe R., Pai C.I., Kehrer T., Cabral E.P., Jangra S., Healy L., Singh G., Warang P., Simon V., Sordillo E.M., van Bakel H., Liu Y., Sun W., Kerwin L., Teijaro J., Schotsaert M., Krammer F., Bresson D., García-Sastre A., Fu Y., Lee B., Powers C., Moran T., Ji H., Tortorella D, & Allen R. (2022). Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants. Med (New York, N.y.), 3(10), 705-721.e11.
+ Open protocol
+ Expand
2

Transgenic Mice for SARS-CoV-2 Research

Check if the same lab product or an alternative is used in the 5 most similar protocols
Female K18-hACE2 transgenic mice were purchased from Jackson laboratory and maintained in pathogen-free conditions and handling conforms to the requirements of the National Institutes of Health and the Scripps Research Institute Animal Research Committee. Harbor H2L2 human antibody transgenic mice (Harbor BioMed, Cambridge, MA) were utilized under a collaboration between the Icahn School of Medicine at Mount Sinai and Harbor BioMed. Eight-to twelve-week old mice were used. Animal studies were approved by the Icahn School of Medicine Institutional Animal Care and Use Committee (IACUC). Female CD-1-IGS mice (strain code #022) were obtained from Charles River at 6–8 weeks of age with a weight range of 22–28.8 g. Animal experiments were approved by Sorrento Therapeutics, Inc. Protocol approval committee and IACUC.
Duty J.A., Kraus T., Zhou H., Zhang Y., Shaabani N., Yildiz S., Du N., Singh A., Miorin L., Li D., Stegman K., Ophir S., Cao X., Atanasoff K., Lim R., Mena I., Bouvier N.M., Kowdle S., Carreño J.M., Rivero-Nava L., Raskin A., Moreno E., Johnson S., Rathnasinghe R., Pai C.I., Kehrer T., Cabral E.P., Jangra S., Healy L., Singh G., Warang P., Simon V., Sordillo E.M., van Bakel H., Liu Y., Sun W., Kerwin L., Teijaro J., Schotsaert M., Krammer F., Bresson D., García-Sastre A., Fu Y., Lee B., Powers C., Moran T., Ji H., Tortorella D, & Allen R. (2022). Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants. Med (New York, N.y.), 3(10), 705-721.e11.
+ Open protocol
+ Expand
3

Transgenic Mouse Models for COVID-19 Research

Check if the same lab product or an alternative is used in the 5 most similar protocols
Female K18-hACE2 transgenic mice were purchased from Jackson laboratory and maintained in pathogen-free conditions and handling conforms to the requirements of the National Institutes of Health and the Scripps Research Institute Animal Research Committee. Harbour H2L2® human antibody transgenic mice (Harbour BioMed, Cambridge, MA) were utilized under a collaboration between the Icahn School of Medicine at Mount Sinai and Harbour BioMed. Eight- to twelve-week old mice were used. Animal studies were approved by the Icahn School of Medicine Institutional Animal Care and Use Committee (IACUC). Female CD-1-IGS mice (strain code #022) were obtained from Charles River at 6–8 weeks of age with a weight range of 22 – 28.8 grams. Animal experiments were approved by Sorrento Therapeutics, Inc. Protocol approval committee and IACUC.
Duty J.A., Kraus T., Zhou H., Zhang Y., Shaabani N., Yildiz S., Du N., Singh A., Miorin L., Li D., Stegman K., Ophir S., Cao X., Atanasoff K., Lim R., Mena I., Bouvier N.M., Kowdle S., Carreño J.M., Rivero-Nava L., Raskin A., Moreno E., Johnson S., Rathnasinghe R., Pai C.I., Kehrer T., Cabral E.P., Jangra S., Healy L., Singh G., Warang P., Simon V., Sordillo E.M., van Bakel H., Liu Y., Sun W., Kerwin L., Teijaro J., Schotsaert M., Krammer F., Bresson D., García-Sastre A., Fu Y., Lee B., Powers C., Moran T., Ji H., Tortorella D, & Allen R. (2022). Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants. Med (New York, N.y.), 3(10), 705-721.e11.
+ Open protocol
+ Expand
4

SARS-CoV-2 Infection in Transgenic Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Female K18-hACE2 transgenic mice were purchased from Jackson laboratory and maintained in pathogen-free conditions and handling conforms to the requirements of the National Institutes of Health and the Scripps Research Institute Animal Research Committee. 8–12 weeks old mice (weight range of 16.2 – 29.1 grams) were infected intranasally with 10,000 PFU of SARS-COV-2 in total volume 50 μL different concentration of AB were injected intravenously 1 h post infection or by intranasal instillation 12 h post infection using Palivizumab as the Isotype control, STI-9167 or STI-9199 depending on the route of administration.
Duty J.A., Kraus T., Zhou H., Zhang Y., Shaabani N., Yildiz S., Du N., Singh A., Miorin L., Li D., Stegman K., Ophir S., Cao X., Atanasoff K., Lim R., Mena I., Bouvier N.M., Kowdle S., Carreño J.M., Rivero-Nava L., Raskin A., Moreno E., Johnson S., Rathnasinghe R., Pai C.I., Kehrer T., Cabral E.P., Jangra S., Healy L., Singh G., Warang P., Simon V., Sordillo E.M., van Bakel H., Liu Y., Sun W., Kerwin L., Teijaro J., Schotsaert M., Krammer F., Bresson D., García-Sastre A., Fu Y., Lee B., Powers C., Moran T., Ji H., Tortorella D, & Allen R. (2022). Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants. Med (New York, N.y.), 3(10), 705-721.e11.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!